3rd Annual Pharma Market Access and Pricing Summit Asia

Day 1 : Wed, 25 Sept 2019

08:00
Registration Starts & Morning Coffee

09:00
Chairperson’s Opening Remarks

Ron Kamienchick, Senior Director, Digital Health, Head of Diagnostics and Personalized Medicine, Teva Pharmaceuticals, United States


PLENARY SESSIONS


09:10
Pharma Transformation Keynote Address
Closing the Digital Divide Between Pharma and The Patient: How is Digital Technology Enabling Patient-Centricity?

Ron Kamienchick, Senior Director, Digital Health, Head of Diagnostics and Personalized Medicine, Teva Pharmaceuticals, United States

09:40
Pharma Leadership Roundtable:
The Next Pharma Industry Priorities: Business, Technology, Regulatory Compliance and Leadership

  • Pharma landscape and evolving regulations
  • Revolutionising the pharma industry towards patient engagement
  • Capturing new revenue streams and markets
  • Leveraging on strategic partnerships and collaborations to drive growth
  • The shift towards value-based pricing
  • Embracing digital transformation – Challenges and opportunities in Asia

Moderator:
Christine Kuan, Market Access and External Affairs Director, Taiwan and South East Asia, Bristol-Myers Squibb, Taiwan

Panellists:
Angela Deluca, Head of Project Planning & Innovation Department, Japan Development, AbbVie, Japan
Sophia Huang, Head of Regulatory Submission Management and Planning Beijing, Bayer Healthcare, China
Amitabh Mishra, President & Chief Technology Officer, Emcure Pharma, India
Jennifer Harmon, Director of Clinical Affairs, SynAgile, Singapore
Zou Bin, Chief Scientific Officer,  AUM Biosciences, Singapore

10.40
Morning Networking & Refreshment Break


Market Access and Pricing Commences
New Market Access Strategies


11:15
Chairperson’s Opening Remarks

Christine Kuan, Market Access and External Affairs Director, Taiwan and South East Asia, Bristol-Myers Squibb, Taiwan

11:20
Market Access in Indonesia

  • Local trends and regulations
  • Payer and Pharma relationship
  • Improving population’s access to drugs

Rizman Abudaeri, Director, Market Access & Regulatory Affairs, AstraZeneca, Indonesia

11:50
Panel: Accelerating Market Access for Medical Devices in APAC

  • Best strategies to promote market access through various stakeholders
  • R&D considerations for efficacy and optimising clinical data
  • Managing partnerships and collaborations
  • Challenges and opportunities of combination products in Asia

Moderator:
Cristan Yang, Country Director, Medtronic, Philippines

Panellists:
Anh Bourcet, Director, ASPAC Health Economics & Market Access, Health Outcomes, Global Orthopedics & Biosurgery, Johnson & Johnson, Singapore
Jung Sungwon, Government Affairs and Market Director, Baxter, Korea

12:30
Your A to Z guide to pricing in Japan [Part 1] Innovation needs innovation

  • An overview of the current drug price setting process in Japan including the limitations
  • A discussion on the potential for a new pricing process to meet the needs of new treatments, and what this may look like
  • A review of the regulatory pathways that have the potential to impact drug price in Japan

Neal Somchand, Principal, Deallus Consulting, Japan

13:00
Networking Lunch

14:00
Driving Market Access, a view from the Medical devices industry

  • How Medtronic looks at market access, building pathways to standards of care
  • Value based healthcare, risk sharing collaborations and business models
  • The rise of healthtech and their role in driving market access and UHC

Cristan Yang, Country Director, Medtronic, Philippines

14:30
Insurance-Pharma Partnership Considerations

  • Insurance sector outlook and impacts
  • Risks and opportunities for Pharma
  • Region potential and benefits to drive market access

Thalia Georgiou, Managing Partner, Healthcare Advisory Asia Pacific, Asia Care Group, Hong Kong

15:00
Accelerating Patient Access via Stakeholder Management

  • Integrating relevant stakeholders into the process
  • Challenges and benefits of the strategy

Christine Kuan, Market Access and External Affairs Director, Taiwan and South East Asia, Bristol-Myers Squibb, Taiwan

15:30
Afternoon Networking & Refreshment Break


 Digital Disruption, RWE and HEOR


16:00
South Korea Case Study: Regulatory Landscape and Market Access Trends

  • Korea’s current government policies and regulations
  • Updates on Risk-sharing agreements system
  • Digitalisation of healthcare sector and impacts on market access
  • Move towards patient centric healthcare

Jung Sungwon, Government Affairs and Market Director, Baxter, Korea

16:30
Digital Disruption, Data and Impact on Market Access Decision

Anh Bourcet, Director, ASPAC Health Economics & Market Access, Health Outcomes, Global Orthopedics & Biosurgery, Johnson & Johnson, Singapore

17:00
Chairperson’s Summary and End of Main Conference Day One

Day 2 : Thu, 26 Sept 2019


Pricing Models and Reimbursement Strategies


 08:50
Morning Coffee

09:00
Chairperson’s Opening Remarks

09:10
Managing Price Regulation and Cost Containment

Robert Tan, Market Lead Access Asia, Vifor Pharma, Singapore

09:40
Panel Discussion:
How Would Pricing Strategies Help Manage Increasing Costs?

  • An open discussion on what strategy works best in Asia under different regulations
  • Expediting access to high-priced drugs in emerging markets whilst managing costs
  • Meeting the rising demand in Asia – Managing costs against reimbursement
  • Measures to manage costs in rare diseases and oncology space
  • Achieving price stability- challenges and opportunities
  • Addressing rising cost trends in therapeutics

Panellists:
Teresa Dioko, Head of Market Access and Public Affairs, Novo Nordisk, Philippines
Jun Feng, Market Access Associate Director, Asia, Abbvie, Singapore
Robert Tan, Market Lead Access Asia, Vifor Pharma, Singapore
Priya Narayan Matzen, Director APAC, Strategic Pricing and Policy, Janssen, Singapore
More panellists to be confirmed

10:40
Morning Networking and Refreshment Break

11:10
Your A to Z guide to pricing in Japan [Part 2] A cut above the rest: Is Japan going too far?

  • An overview of all the price adjustment rules currently in place in Japan
  • A review of Japan’s most recent price control measure – the HTA system, together with the recent changes of the price maintenance premium
  • A discussion around what the future price adjustment landscape may look like

Yuki Sato, Representative Director, Deallus Consulting, Japan

11:40
Comparison of Regional Pricing Strategies

  • Highlights in key markets: Japan, China, Singapore
  • Challenges and benefits of respective pricing models
  • Vietnam: Improving accessibility and changing reimbursement landscape

Priya Narayan Matzen, Director APAC, Strategic Pricing and Policy, Janssen, Singapore

Co-presenter:
Laurie Kan, Senior Regional Market Access Manager, Southeast Asia, Johnson and Johnson, Singapore

12:10
Networking Lunch

13:10
Pricing Regulation Analysis in Asia: Case Study of Philippines

  • Market access considerations in a UHC environment
  • Regional price regulation analysis

Teresa Dioko, Head of Market Access and Public Affairs, Novo Nordisk, Philippines


Market Segments in Focus


13:50
China Case Study:
Henlius’ Biosimilars Market Entry

  • Potential of biosimilars in China
  • Market access challenges and regulatory requirements
  • Henlius’ approach to improve biosimilars uptake

Jeremy Chien, Marketing Director, Shanghai Henlius, China

14:30
Afternoon Networking & Refreshment Break

15:00
Innovating Business Models to Maximize Access for Thais

  • Managing challenges and regulations in Thailand
  • Innovation in value creation and delivery

Sittipong Liamsuwan, Policy and Access Director, MSD, Thailand

15:30
RWE Data Strategy for Clinical Trials:

  • Leveraging Randomised Clinical Trials to Generate Real-World Evidence
  • Selection of interventions appropriate in clinical care settings
  • Potential usefulness of real-world evidence to support regulatory decision-making
  • Addressing potential challenges around blinding, randomisation and bias

Nir Arbel, Co-Founder and Chief Executive Officer, Carmentix, Singapore

16:00
Chairperson’s Summary and End of Main Conference